adenine has been researched along with idelalisib in 94 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 82 (87.23) | 24.3611 |
| 2020's | 12 (12.77) | 2.80 |
| Authors | Studies |
|---|---|
| Burger, JA | 1 |
| Flinn, IW | 1 |
| Alinari, L; Baiocchi, RA; Christian, B | 1 |
| Wiestner, A | 1 |
| Burke, RT; Druker, BJ; Loriaux, MM; Prins, RC; Spurgeon, SE; Tyner, JW | 1 |
| Danilov, AV | 1 |
| Brown, JR; O'Brien, SM; Porter, DL | 1 |
| Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA | 1 |
| Guo, S; Li, Q; Qu, F; Wang, Y; Xia, B; Yang, H; Yuan, T; Zhang, Q; Zhang, Y; Zhao, W | 1 |
| Beurskens, FJ; Breij, EC; Da Roit, F; Engelberts, PJ; Golay, J; Gritti, G; Introna, M; Parren, PW; Rambaldi, A; Taylor, RP | 1 |
| Buggins, AG; Devereux, S; Fegan, C; Forconi, F; Jones, CH; Pepper, C; Pratt, G; Stevenson, FK; Walsby, EJ | 1 |
| Niemann, CU | 1 |
| Chung, C; Lee, R | 1 |
| Sinha, G | 1 |
| Abdul-Hay, M; Desai, AV; El-Bakkar, H | 1 |
| Cao, Y; Castillo, JJ; Chen, J; Davids, MS; Hatjiharissi, E; Hunter, ZR; Kanan, S; Liu, X; Treon, SP; Tsakmaklis, N; Xu, L; Yang, G | 1 |
| Pettitt, AR; Slupsky, JR; Till, KJ | 1 |
| Molica, S | 2 |
| Borah, BJ; Call, TG; Chaffee, KG; Chanan-Khan, AA; Ding, W; Finnes, HD; Kay, NE; Leis, JF; Parikh, SA; Shanafelt, TD; Slager, SL | 1 |
| Burger, JA; Keating, MJ; O'Brien, SM; Sanford, DS; Wierda, WG | 1 |
| Bergmann, M; Wendtner, CM | 1 |
| de Rooij, MF; Kater, AP; Kersten, MJ; Kuil, A; Pals, ST; Spaargaren, M | 1 |
| Müschen, M | 1 |
| Balakrishnan, K; Burger, JA; Faia, K; Fu, M; Gandhi, V; Keating, MJ; Kutok, JL; O'Brien, S; Peluso, M; Rosin, NY; Wierda, WG | 1 |
| Fiorcari, S; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Potenza, L | 1 |
| Gentile, M; Morabito, F; Polliack, A; Seymour, JF | 1 |
| Lamanna, N | 1 |
| Feugier, P; Michallet, AS; Ysebaert, L | 1 |
| Bayerl, S; Dreyling, M; Hiddemann, W; Hutter, G; Zimmermann, Y; Zoellner, AK | 1 |
| Goede, V; Hallek, M | 1 |
| Burger, JA; Sivina, M | 1 |
| de Rooij, MF; Kersten, MJ; Kraan, W; Kuil, A; Pals, ST; Spaargaren, M; Treon, SP | 1 |
| Woyach, JA | 1 |
| Dearden, C | 1 |
| Arimany-Nardí, C; Aymerich, M; Cabezas, S; Campo, E; Clot, G; Colomer, D; Jiménez, L; Lee-Vergés, E; López-Guerra, M; López-Guillermo, A; Montraveta, A; Pastor-Anglada, M; Pérez-Galán, P; Pinyol, M; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S | 1 |
| Gaidano, G; Ghia, P; Malcikova, J; Montserrat, E; Moreno, C; Pospisilova, S; Rosenquist, R; Rossi, D; Stamatopoulos, K; Sutton, LA; Tausch, E | 1 |
| Barassi, C; Bernasconi, E; Bertoni, F; Cascione, L; Gaudio, E; Goodstal, S; Kwee, I; Ponzoni, M; Rinaldi, A; Stathis, A; Tarantelli, C; Targa, A; Zucca, E | 1 |
| Bojarczuk, K; Efremov, DG; Gobessi, S; Innocenti, I; Laurenti, L; Pozzato, G; Sasi, BK | 1 |
| Cheson, BD | 1 |
| Brown, JR; Hallek, MJ; Pagel, JM | 1 |
| Andrews, DW; Brauer, PM; Hariharan, S; Leber, B; Oakes, CC; Oppermann, S; Shi, Y; Spaner, DE; Ylanko, J; Zúñiga-Pflücker, JC | 1 |
| Marini, BL; Perissinotti, AJ; Samanas, L | 1 |
| Bachow, SH; Barr, PM; Cheson, BD; Claxton, DF; Evens, AM; Feldman, T; Fitzpatrick, DM; Goy, A; Hill, BT; Howlett, C; Kaur, G; Kiselev, P; Lamanna, N; Landsburg, DJ; Mato, AR; Nabhan, C; Nasta, SD; Porter, D; Pu, JJ; Schuster, SJ; Sehgal, AR; Skarbnik, AP; Strelec, LE; Svoboda, J; Ujjani, CS; Vandegrift, A; Zent, CS | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; Reinhardt, HC | 1 |
| Koffman, B; Schorr, A | 1 |
| Jeyakumar, D; O'Brien, S | 1 |
| Feiz Barazandeh, A; Jia, P; Keynan, Y; Khadem, F; Liu, D; Mou, Z; Uzonna, JE | 1 |
| Diels, J; Dorman, E; Sengupta, N; Sorensen, S; Trambitas, C; van Sanden, S; Wildgust, M; Xu, Y | 1 |
| Alt, FW; Ambrogio, C; Blasco, RB; Brown, JR; Cheong, TC; Chiarle, R; Compagno, M; Gostissa, M; Karaca, E; Kasar, SN; Langellotto, F; Meng, FL; Pighi, C; Poggio, T; Sun, J; Voena, C; Wang, Q; Wiestner, A; Wu, CJ; Yeap, LS | 1 |
| Abrisqueta, P; Bosch, F; Delgado, J; García-Marco, JA; Giraldo, P; González, M; Hernández-Rivas, JA; Jarque, I; Loscertales Pueyo, J; Martínez, R; Ramírez Payer, Á; Terol, MJ; Yáñez, L | 1 |
| Dreyling, M; Hallek, M; Jerkeman, M; Kimby, E; Staudt, L; Thieblemont, C | 1 |
| Acuña, C; Alfaro, J; Almirez, RG; Avila, P; Barde, A; Belmar, S; Bernales, S; Chakravarty, S; Chauhan, S; Delgado, L; Flores, C; Fuentealba, G; Gaete, D; Hung, DT; Kanno, S; McCullagh, E; Nayak, AK; Patel, D; Pérez de Arce, F; Pham, SM; Pujala, B; Quinn, KP; Rai, R; Sharma, VK; Upendra, TVR; Ureta, G | 1 |
| Hill, BT; Waldron, M; Winter, A | 1 |
| Bence-Bruckler, I; Coutre, S; Delage, R; Owen, CJ; Shustik, C; Toze, CL | 1 |
| Barr, PM; Brander, DM; Cheson, BD; Claxton, DF; Cruz, AL; Daniel, C; Fanning, M; Foon, K; Gashonia, L; Goy, A; Henick Bachow, S; Hill, BT; Howlett, C; Isaac, K; Kennard, KH; Kiselev, P; Lamanna, N; Lenhart, J; Mato, AR; Nabhan, C; Pu, JJ; Schuster, SJ; Skarbnik, AP; Svoboda, J; Timlin, C; Ujjani, CS; Winter, AM; Yacur, M; Zent, CS | 1 |
| Edelmann, J; Gribben, JG | 1 |
| de Weerdt, I; Kater, AP; Koopmans, SM; van Gelder, M | 1 |
| Bastie, JN; Brion, A; Dartigeas, C; de Guibert, S; Delmer, A; Dupuis, J; Ghez, D; Godet, S; Herbaux, C; Leblond, V; Protin, C; Quinquenel, A; Ysebaert, L | 1 |
| Best, OG; Christopherson, RI; Mulligan, SP; Shen, Y | 1 |
| Davids, MS | 1 |
| Eichhorst, B; Hallek, M; Shanafelt, TD | 1 |
| Brander, DM; Gauthier, G; Mato, AR; Samp, JC; Terasawa, E | 1 |
| Mato, A; Rhodes, J; Sharman, JP | 1 |
| Budziszewska, BK; Czyż, J; Długosz-Danecka, M; Gil, L; Iskierka-Jażdżewska, E; Jamroziak, K; Kopacz, A; Lech-Marańda, E; Puła, B; Rybka, J; Subocz, E; Szymczyk, A; Warzocha, K; Waszczuk-Gajda, A; Zawirska, D | 1 |
| Göckeritz, E; Hallek, M; Hassenrück, F; Herter, S; Klein, C; Knödgen, E; Krause, G; Midda, SH; Neumann, L; Vondey, V | 1 |
| Pleyer, C; Sun, C; Wiestner, A | 1 |
| Reagan, PM; Rodgers, TD | 1 |
| Bonaldi, L; Burei, M; Facco, M; Frezzato, F; Gregianin, M; Imbergamo, S; Piazza, F; Pizzi, M; Pravato, S; Scomazzon, E; Semenzato, G; Trentin, L; Vio, S; Visentin, A | 1 |
| Bertoni, F; Cascione, L; Gaudio, E; Stathis, A; Tarantelli, C; Zucca, E | 1 |
| Patil, N; Went, RG | 1 |
| Henley, P; Man, S | 1 |
| Aurran, T; Béné, MC; Collignon, A; Dartigeas, C; de Guibert, S; Delmer, A; Dilhuydy, MS; Dmytruk, N; Dupuis, J; Durot, E; Ghez, D; Gilardin, L; Godet, S; Lepretre, S; Lévy, V; Merabet, F; Ohanyan, H; Quinquenel, A; Roos Weil, D; Toussaint, E; Vignon, M; Ysebaert, L | 1 |
| Autore, F; Corbingi, A; Criscuolo, M; Fianchi, L; Innocenti, I; Laurenti, L; Morelli, F; Pagano, L; Sica, S; Sorà, F | 1 |
| Barosi, G; Gaidano, G; Girmenia, C; Marchetti, M; Pane, F; Rambaldi, A; Tura, S; Zinzani, PL | 1 |
| Bhargava, P; Byrd, JC; Chanan-Khan, AA; Darif, M; Dreiling, LK; Ferrante, L; Furman, RR; Hillmen, P; Howes, A; James, DF; Jones, J; Kay, NE; Londhe, A; Mobasher, M; Mun, Y; Ni, A; Rabe, KG; Reddy, V; Seymour, JF; Shanafelt, TD; Sharman, JP; Soumerai, JD; Stark, T; Xing, G; Zelenetz, AD | 1 |
| Akritidou, MA; Anagnostopoulos, A; Belloni, D; Chartomatsidou, E; Ferrero, E; Ghia, P; Kotta, K; Ntoufa, S; Papakonstantinou, N; Rosenquist, R; Rovida, A; Stamatopoulos, K; Stavroyianni, N; Trangas, T | 1 |
| Autore, F; Ciolli, S; Coscia, M; Cuneo, A; D'Arena, G; Del Poeta, G; Efremov, DG; Foà, R; Frustaci, A; Gentile, M; Ibatici, A; Innocenti, I; Laurenti, L; Levato, L; Mauro, FR; Morelli, F; Murru, R; Piciocchi, A; Reda, G; Rigolin, GM; Scarfò, L; Schiattone, L; Sportoletti, P; Tedeschi, A; Trentin, L | 1 |
| de Boer, R; de Weerdt, I; Eldering, E; Hofland, T; Kater, AP; Tannheimer, S; Ter Burg, H; Tonino, SH | 1 |
| Aguilar-Company, J; Los-Arcos, I; Ruiz-Camps, I | 1 |
| Gutierrez, C; Wu, CJ | 1 |
| Ahmed, J; Aksoy, E; Alusi, G; Burns, E; Chard Dunmall, LS; Ferguson, MS; Gangeswaran, R; Hiley, C; Lemoine, NR; Marelli, G; Tysome, JR; Vanhaesebroeck, B; Wang, Y; Whitehead, MA | 1 |
| Allain, EP; Bat, V; Caron, P; Demirtas, D; Droit, A; Guillemette, C; Hubmann, R; Jäger, U; Joly-Beauparlant, C; Labriet, A; Le, T; Lévesque, E; Rouleau, M; Schnabl, S; Shehata, M; Staber, PB; Tremblay, S; Turcotte, V; Vaillancourt, J; Vanura, K; Villeneuve, L | 1 |
| Anagnostopoulos, A; Chatzidimitriou, A; Galigalidou, C; Gemenetzi, K; Ghia, P; Ioannou, N; Iskas, M; Koravou, E; Kotouza, M; Kotta, K; Kouvatsi, A; Papazoglou, D; Pasentsis, K; Psomopoulos, F; Ramsay, AG; Scarfó, L; Stamatopoulos, K; Stavroyianni, N; Vardi, A; Vlachonikola, E | 1 |
| Budziszewska, BK; Długosz-Danecka, M; Gil, L; Hus, M; Iskierka-Jażdżewska, E; Jamroziak, K; Jurczak, W; Lech-Marańda, E; Osowiecki, M; Piszczek, W; Puła, B; Rybka, J; Salomon-Perzyński, A; Steckiewicz, P; Subocz, E; Szukalski, Ł; Szymczyk, A; Waszczuk-Gajda, A; Zaucha, JM | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; von Tresckow, J | 1 |
| Busca, A; Candoni, A; Cattaneo, C; Dargenio, M; Facchinelli, D; Fanci, R; Farina, F; Laurenti, L; Lessi, F; Marchesi, F; Marchesini, G; Nadali, G; Pagano, L; Picardi, M; Prezioso, L; Spolzino, A; Tisi, MC; Trastulli, F; Verga, L; Visentin, A | 1 |
| Cavallini, C; Chignola, R; Dando, I; Donadelli, M; Galasso, M; Krampera, M; Lovato, O; Pizzolo, G; Pozza, ED; Romanelli, MG; Scupoli, MT | 1 |
| Avsec, D; Gobec, M; Jakopin, Ž; Markovič, T; Mlinarič-Raščan, I; Nabergoj, S; Podgornik, H | 1 |
| Al-Janazreh, H; Angeletti, I; Biagi, A; Bomben, R; Bossio, S; Cassin, R; Chiarenza, A; Condoluci, A; Consoli, U; Coscia, M; Cuneo, A; Cutrona, G; D'Arrigo, G; Del Giudice, I; Del Poeta, G; Di Raimondo, F; Ferrarini, M; Foà, R; Fronza, G; Gaidano, G; Galimberti, S; Gattei, V; Gentile, M; Herishanu, Y; Jaksic, O; Laurenti, L; Loseto, G; Martino, EA; Mauro, FR; Mendicino, F; Menichini, P; Moia, R; Monti, P; Morabito, F; Murru, R; Neri, A; Pietrasanta, D; Polliack, A; Rago, A; Reda, G; Rossi, D; Rossi, FM; Scortechini, I; Sportoletti, P; Trentin, L; Tripepi, G; Varettoni, M; Vigna, E; Visentin, A; Zucchetto, A | 1 |
| Boccadoro, M; Boccellato, E; Cassin, R; Coscia, M; Cuneo, A; De Paoli, L; Foà, R; Gaidano, G; Gentile, M; Griggio, V; Laurenti, L; Marchetti, M; Mauro, FR; Montalbano, MC; Murru, R; Orsucci, L; Pennese, E; Perutelli, F; Porrazzo, M; Reda, G; Rigolin, GM; Rivela, P; Salvetti, C; Scarfò, L; Schiattone, L; Tedeschi, A; Trentin, L; Vassallo, F; Visentin, A; Vitale, C; Zamprogna, G | 1 |
| Alonso, C; Ángel Hernández-Rivas, J; Bastidas, G; Bastos-Oreiro, M; Bocanegra, A; Carpio, C; Comai, A; Cordoba, R; De Nicolás, R; Del Campo, R; Fernández-Cruz, A; García-Suárez, J; Grande, C; Jiménez-Ubieto, A; López-Guillermo, A; López-Jiménez, J; Luis Plana, J; Marquet, J; Martín, X; Martínez-López, J; Mas-Ochoa, C; Morillo, D; Navarro-Matilla, B; Núñez, L; Prat, M; Romero, S; Ruiz-Camps, I; Seri, C; Serna, Á; Stefania Infante, M; Vásquez, L; Villafuerte, P | 1 |
39 review(s) available for adenine and idelalisib
| Article | Year |
|---|---|
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Oxazines; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Risk Factors; Signal Transduction | 2012 |
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Medical Oncology; Morpholines; Mutation; NF-kappa B; Oxazines; Phosphatidylinositol 3-Kinases; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; src-Family Kinases | 2012 |
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; B-Lymphocytes; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction | 2013 |
Novel treatments for chronic lymphocytic leukemia and moving forward.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Small Molecule Libraries; Sulfonamides; Vidarabine | 2014 |
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine | 2014 |
[Targeted treatment of chronic lymphocytic leukaemia].
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Oxazines; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Sulfonamides | 2014 |
Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2014 |
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Flavonoids; Humans; Immunologic Factors; Indolizines; Isoquinolines; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyridinium Compounds; Pyrimidines; Quinazolinones; Receptors, Antigen, T-Cell; Sulfonamides; Thalidomide | 2015 |
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2015 |
Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.
Topics: Adenine; DNA-Binding Proteins; Humans; Molecular Targeted Therapy; Piperidines; Pre-B Cell Receptors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cells, B-Lymphoid; Proto-Oncogene Proteins c-bcl-6; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; STAT5 Transcription Factor | 2015 |
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Topics: Adenine; Antineoplastic Agents; Humans; Killer Cells, Natural; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Signal Transduction; Tumor Microenvironment | 2015 |
Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Class Ia Phosphatidylinositol 3-Kinase; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Treatment Outcome | 2015 |
Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Cost-Benefit Analysis; Creatinine; Decision Making; Geriatric Assessment; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Life Expectancy; Molecular Targeted Therapy; Patient Selection; Piperidines; Precision Medicine; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2015 |
Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.
Topics: Adenine; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2015 |
The importance of the tissue microenvironment in hairy cell leukemia.
Topics: Adenine; Antineoplastic Agents; B-Lymphocytes; Bone Marrow; CD40 Antigens; Gene Expression Regulation, Leukemic; Humans; Intercellular Adhesion Molecule-1; Leukemia, Hairy Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Receptors, CXCR4; Signal Transduction; Spleen; Tumor Microenvironment; Vascular Cell Adhesion Molecule-1 | 2015 |
Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management.
Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Remission Induction; Risk Factors; Signal Transduction | 2015 |
Speed bumps on the road to a chemotherapy-free world for lymphoma patients.
Topics: Adenine; Clinical Trials as Topic; Drug Design; Humans; Lymphoma; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2016 |
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides; Vidarabine | 2016 |
Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2017 |
Current strategies to create tailored and risk-adapted therapies for CLL patients.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase II as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Precision Medicine; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Risk Factors; Sulfonamides | 2016 |
The 21st century revolution in CLL: Why this matters to patients.
Topics: Adenine; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; History, 21st Century; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Precision Medicine; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2016 |
B cell receptor inhibition as a target for CLL therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Age Factors; Atrial Fibrillation; Diarrhea; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytosis; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pneumonia; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell | 2016 |
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2017 |
Targeting of B-cell receptor signalling in B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Waldenstrom Macroglobulinemia | 2017 |
Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Interactions; Food-Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides | 2017 |
Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides | 2017 |
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Drug Therapy; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Recurrence; Sulfonamides; Transplantation, Homologous | 2017 |
Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Remission Induction; Sulfonamides; Tumor Suppressor Protein p53 | 2017 |
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease Management; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Severity of Illness Index | 2017 |
How should we sequence and combine novel therapies in CLL?
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Smith-Magenis Syndrome; Sulfonamides | 2017 |
Chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Diagnosis, Differential; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Recurrence; Risk Factors; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.
Topics: Adenine; Antineoplastic Agents; Atrial Fibrillation; B-Lymphocytes; Bridged Bicyclo Compounds, Heterocyclic; Hemorrhage; Humans; Lymphoma, Non-Hodgkin; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Sulfonamides | 2018 |
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Autoimmunity; B-Lymphocytes; Cell Communication; Humans; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2018 |
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Topics: Adenine; Antineoplastic Agents; Drug Design; Humans; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell | 2018 |
Chronic lymphocytic leukaemia: the role of T cells in a B cell disease.
Topics: Adenine; B-Lymphocytes; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; T-Lymphocyte Subsets | 2019 |
Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Hematology; Humans; Infection Control; Infections; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Practice Guidelines as Topic; Purines; Pyrazoles; Pyrimidines; Quality of Life; Quinazolinones | 2019 |
Risk of infection associated with new therapies for lymphoproliferative syndromes.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Communicable Disease Control; Humans; Immune Checkpoint Inhibitors; Infections; Lymphoproliferative Disorders; Piperidines; Purines; Pyrazines; Quinazolinones; Risk; Rituximab; Sulfonamides; Syndrome | 2020 |
Clonal dynamics in chronic lymphocytic leukemia.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Genome-Wide Association Study; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides; Transcriptome; Whole Genome Sequencing | 2019 |
[Current diagnosis and treatment of chronic lymphocytic leukaemia].
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Comorbidity; Drug Approval; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Piperidines; Prognosis; Purines; Quinazolinones; Rituximab; Smith-Magenis Syndrome; Sulfonamides | 2020 |
3 trial(s) available for adenine and idelalisib
| Article | Year |
|---|---|
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
Topics: Adenine; Autoimmune Diseases; Disease-Free Survival; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Survival Rate | 2019 |
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience.
Topics: Adenine; Adolescent; Adult; Child; Female; Follow-Up Studies; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Prevalence; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Retrospective Studies; Risk Factors | 2019 |
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Purines; Quinazolinones; Sulfonamides | 2021 |
52 other study(ies) available for adenine and idelalisib
| Article | Year |
|---|---|
B-cell receptor inhibitors in chronic lymphocytic leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Standard of Care | 2011 |
Novel targeted therapies for mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antigens, Differentiation, B-Lymphocyte; B-Lymphocytes; Cell Cycle; Clinical Trials as Topic; Cyclin D1; DNA Repair; Female; Histocompatibility Antigens Class II; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Targeted Therapy; NF-kappa B; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-akt; Purines; Pyrazoles; Pyrimidines; Quinazolinones; TOR Serine-Threonine Kinases; Translocation, Genetic | 2012 |
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthyridines; Phenazines; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Vidarabine | 2013 |
Idelalisib, ibrutinib show benefits in CLL.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2014 |
[Effect of PI3Kδ inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].
Topics: Adenine; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Multiple Myeloma; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrazoles; Pyrimidines; Quinazolinones | 2014 |
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Topics: Adenine; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Case-Control Studies; Cell Proliferation; Cells, Cultured; Complement Activation; Flow Cytometry; Fluorescent Antibody Technique; Humans; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Macrophages; Neutrophils; Phagocytosis; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2015 |
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Class I Phosphatidylinositol 3-Kinases; Cyclams; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Heterocyclic Compounds; Humans; Immunoglobulin Heavy Chains; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Natalizumab; Piperidines; Prognosis; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, CXCR4; Signal Transduction; Survival Analysis | 2015 |
Overcoming mantle cell lymphoma's ibrutinib resistance.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinases; Cysteine; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Serine | 2014 |
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bridged Bicyclo Compounds, Heterocyclic; Drug Synergism; Humans; Membrane Proteins; Piperidines; Proto-Oncogene Proteins; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sulfonamides; Waldenstrom Macroglobulinemia | 2015 |
Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents; B-Lymphocytes; Case-Control Studies; Cell Movement; Class I Phosphatidylinositol 3-Kinases; Gene Expression Regulation, Leukemic; Germinal Center; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lysophospholipids; Morpholines; Oxazines; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; Syk Kinase | 2015 |
Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Drug Discovery; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; San Francisco; Societies, Medical | 2015 |
Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
Topics: Adenine; Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Health Expenditures; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medicare Part D; Minnesota; Models, Economic; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Time Factors; Treatment Outcome; United States | 2015 |
[Chronic lymphatic leukemia].
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Remission Induction; Rituximab; Vidarabine | 2015 |
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Adhesion; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Proto-Oncogene Proteins c-bcr; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Tumor Cells, Cultured | 2015 |
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Topics: Adenine; Aged; Aged, 80 and over; Apoptosis; Bone Marrow Cells; Case-Control Studies; Cell Proliferation; Cell Survival; Chemokine CCL3; Chemokine CCL4; Chemotaxis; Female; Humans; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Prognosis; Proto-Oncogene Proteins c-akt; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Ribosomal Protein S6 Kinases; Signal Transduction; Stromal Cells | 2015 |
Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2015 |
Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Humans; Lymphoma, Large B-Cell, Diffuse; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Sirolimus | 2015 |
Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemokine CXCL12; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha4beta1; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Piperidines; Plasma Cells; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Receptors, CXCR4; Signal Transduction; Vascular Cell Adhesion Molecule-1; Waldenstrom Macroglobulinemia | 2016 |
Management of prolymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Disease Progression; Humans; Immunophenotyping; Immunotherapy; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Mutation; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Recurrence; Stem Cell Transplantation; T-Lymphocytes; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Bendamustine Hydrochloride; Cell Proliferation; Female; Follow-Up Studies; Humans; Lectins, C-Type; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcriptome; Tumor Cells, Cultured | 2016 |
Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alleles; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Class I Phosphatidylinositol 3-Kinases; Gene Expression; Gene Frequency; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Prognosis; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides; Tumor Suppressor Protein p53 | 2016 |
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell; MAP Kinase Kinase Kinases; Mice; Molecular Targeted Therapy; Niacinamide; Piperidines; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Oxazines; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Sulfonamides | 2016 |
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
Topics: Adenine; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cellular Microenvironment; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Imaging, Three-Dimensional; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Quinazolinones; Reproducibility of Results; Signal Transduction; Stromal Cells; Sulfonamides; Sunitinib; Up-Regulation | 2016 |
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Proportional Hazards Models; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2016 |
Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis.
Topics: Adenine; Amphotericin B; Animals; CD4 Lymphocyte Count; Class I Phosphatidylinositol 3-Kinases; Cytokines; Drug Therapy, Combination; Female; Immunomodulation; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Liver; Lymph Nodes; Mice; Mice, Inbred BALB C; Parasite Load; Phosphoinositide-3 Kinase Inhibitors; Purines; Quinazolines; Quinazolinones; Spleen; T-Lymphocytes, Regulatory | 2017 |
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cytidine Deaminase; Enzyme Inhibitors; Female; Genomic Instability; Humans; Immunoglobulin Class Switching; Immunoglobulin Heavy Chains; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Recombination, Genetic; Somatic Hypermutation, Immunoglobulin; Translocation, Genetic | 2017 |
Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Sulfonamides | 2017 |
Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Death; Cell Line; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction | 2017 |
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Proportional Hazards Models; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Retrospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2017 |
Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies).
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sequence Deletion; Sulfonamides; Tumor Suppressor Protein p53 | 2017 |
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
Topics: Adenine; Drug Substitution; France; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Retrospective Studies; Treatment Outcome | 2018 |
Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
Topics: Adenine; Animals; Antigens, CD; Cell Adhesion; Coculture Techniques; Fibroblasts; Humans; Immunophenotyping; L Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Mice; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Tumor Cells, Cultured; Tumor Microenvironment | 2018 |
Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Disease Progression; Disease-Free Survival; Drug Substitution; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Medication Adherence; Middle Aged; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Treatment Outcome | 2018 |
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Poland; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Retrospective Studies; Rituximab | 2018 |
Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; B-Lymphocytes; Benzamides; Cell Line, Tumor; Cytotoxins; Humans; Killer Cells, Natural; Leukocytes, Mononuclear; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Rituximab | 2018 |
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Treatment Outcome | 2019 |
In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Humans; Isoquinolines; Lymphoma; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2019 |
Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors.
Topics: Adenine; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Substitution; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Retreatment; Rituximab; Signal Transduction; Sulfonamides; Treatment Outcome | 2019 |
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Topics: Adenine; Antineoplastic Agents; beta 2-Microglobulin; Bridged Bicyclo Compounds, Heterocyclic; Databases, Factual; Female; Hemoglobins; Humans; Immunotherapy; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Prognosis; Proportional Hazards Models; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sulfonamides; Survival Rate | 2019 |
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Bridged Bicyclo Compounds, Heterocyclic; Down-Regulation; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histones; Humans; Indazoles; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyridones; Pyrimidines; Quinazolinones; Signal Transduction; Sulfonamides; Tumor Microenvironment | 2019 |
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Disease Progression; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Retrospective Studies; Sulfonamides | 2019 |
Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Cell Survival; Humans; Imidazoles; Janus Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mice; NIH 3T3 Cells; Nitriles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolinones | 2019 |
Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.
Topics: Adenine; Administration, Intravenous; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Female; Immunotherapy; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Oncolytic Viruses; Purines; Quinazolines; Quinazolinones; Transplantation, Homologous; Treatment Outcome; Tumor Burden; Vaccinia virus | 2020 |
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Pharmacological; Female; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mass Spectrometry; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Piperidines; Purines; Quinazolinones; Vidarabine | 2020 |
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clonal Evolution; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunological Synapses; Immunophenotyping; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Piperidines; Purines; Quinazolinones; Rituximab; T-Lymphocytes; Vidarabine | 2020 |
Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prognosis; Proto-Oncogene Proteins c-bcr; Purines; Quinazolinones; Retrospective Studies; Salvage Therapy; Survival Rate; Tumor Suppressor Protein p53 | 2020 |
Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Bacterial Infections; Case-Control Studies; Enzyme Inhibitors; Female; Humans; Invasive Fungal Infections; Italy; Lymphoproliferative Disorders; Male; Middle Aged; Molecular Targeted Therapy; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Purines; Quinazolinones; Retrospective Studies; Risk Factors; Virus Diseases | 2021 |
Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Purines; Quinazolinones; Receptors, Antigen, B-Cell; Rituximab; Signal Transduction | 2021 |
EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells.
Topics: Adenine; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Drug Synergism; Humans; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Piperidines; Purines; Pyrrolidinones; Quinazolinones; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Tetrazoles; U937 Cells | 2021 |
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Immunoglobulins; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Proportional Hazards Models; Purines; Quinazolinones; Recurrence; Retreatment; Rituximab; Treatment Outcome | 2021 |
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
Topics: Adenine; Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunocompromised Host; Infections; Lymphopenia; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazines; Quinazolinones; Retrospective Studies; Risk Factors; Sulfonamides; Young Adult | 2021 |